Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast CAncer

Next Previous
Trial Profile

Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast CAncer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Palbociclib (Primary) ; Goserelin; Letrozole; Tamoxifen
  • Indications Adenocarcinoma; Advanced breast cancer; Early breast cancer; HER2 negative breast cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms NeoRHEA

    • Most Recent Events

    • 06 Jun 2023 Secondary analysis evaluating circulating tumor DNA (ctDNA) assays monitoring in patients with breast cancer, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
    • 06 Jun 2023 Results (n=73) evaluating baseline clinicopathological characteristics, RNA-seq derived PAM50 subtypes and mRNA expression of ESR1, Ki67, CCNE1, RB1 and CDK6 single genes according to US response and CCCA, presented at the 59th Annual Meeting of the American Society of Clinical Oncology
    • 30 May 2023 According to a NeoGenomics media release, data from this trial will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top